Researchers at UCD


Catherine Kelly

Clinical Lecturer/Assistant Professor

School Of Medicine



Dr Catherine M. Kelly is a Consultant Medical Oncologist at the Mater Misericordiae University Hospital, Mater Private Hospital and Cavan General Hospital.  Dr Kelly is Chair of Cancer Trials Ireland, Breast Cancer Clinical Trials Group.  Dr Kelly completed specialist Medical Oncology training in Dublin teaching hospitals and leading UK institutions; The Royal Marsden Hospital, and St Bartholomew¿s Hospital London, UK.  She has Fellowships in Medical Oncology and Breast Medical Oncology from Toronto-Sunnybrook, Odette Cancer Center, Canada and The University of Texas, M.D Anderson Cancer Center, Houston, USA (competitively awarded the Susan G. Komen Interdisciplinary breast cancer fellowship).  Dr Kelly is widely published in breast cancer (JCO, JNCI, The Oncologist, BMJ, Lancet Oncology, Breast Cancer Research, Cancer, Annals of Oncology, Drugs etc) with over 40 peer reviewed publications.  She is an international editor for the Journal of Clinical Oncology.  She serves on the board of the National Cancer Registry of Ireland, Cancer Trials Ireland and the HPRA Clinical Trials Subcommittee.  She is lead author of a large phase III Adjuvant Breast Cancer Clinical Trial and is National Principal Investigator for many international phase II and III clinical trials in early and metastatic breast cancer.  Dr Kelly is currently a member of the steering committee of an  EORTC/US consortium examining retrospectively and prospectively male breast cancer.  She is involved in the several tissue microarray projects that will aim to develop prognostic and predictive panels for breast cancer.  She is Co-Principal investigator on a project examining interventions to improve adherence to endocrine therapies and is Principal investigator of a Nationals study examining the understanding and perceptions of clinical trials among patients with cancer.


Honours and Awards

Year: 2005.
Title: Corrigan Medal Finalist, RCPI. (Presentation of communication tool used by oncologists (adjuvant online)
Year: 2007.
Title: EORTC/ASCO/NCI Award, Biomarkers in Breast Cancer. (Breast Cancer Biomarker research conducted at the Conway Institute, UCD)
Year: 2008.
Title: Novartis Oncology Young Canadian Investigator Award (NOYCIA). (Breast Cancer Biomarker research conducted at the Conway Institute, UCD)
Year: 2008.
Title: American Society of Clinical Oncology Foundation Merit Award (Breast Cancer Biomarker research conducted at the Conway Institute, UCD)
Year: 2009.
Title: San Antonio Breast Cancer Symposium Clinical Scholars Scholarship (Health Services Research)
Year: 2010.
Title: 2010 Thomas & Edna Naylor Memorial Award, Best Thesis Paper 2009/10 for University of Toronto


Association: National Cancer Registry of Ireland (NCRI), Function/Role: Ministerial appointee to the board
Association: Cancer Trials Ireland, Function/Role: Elected Board Member
Association: Cancer Trials Ireland Breast Cancer Group (Formerly ICORG), Function/Role: Chair
Association: First international consensus guidelines panel for breast cancer in young women (BCY1). , Function/Role: Member
Association: European Society of Medical Oncology, Function/Role: Member
Association: American Society of Clinical Oncology, Function/Role: Member
Association: Irish Society of Medical Oncology, Function/Role: Member


Committee : National Cancer Control Programme (NCCP) Breast Cancer Guidelines Group
Committee : Pre-Clinical/Clinical Sub-Committee (ACHM Panel I) of the HPRA
Committee : Breast International Group (BIG) Executive Committee
Committee : Breast Cancer Steering Group Eastern Cooperative Oncology Group (ECOG)
Committee : National Breast Tumour Group: National Cancer Control Programme (NCCP), Ireland

Journals Edited

Oncologist: Reviewer.
Expert Opinion On Drug Safety: Reviewer.
European Journal Of Cancer: Reviewer.
Breast Cancer Research And Treatment: Reviewer.
British Journal Of Cancer: Reviewer.
Expert Opinion On Pharmacotherapy: Reviewer.
Journal Of Clinical Oncology: Reviewer.
Expert Opinion On Drug Safety: Editorial Board member.
Expert Opinion On Pharmacotherapy: Editorial Board member.
Journal Of Clinical Oncology: Editorial Board member.



Book Chapters

Harper-Wynne, C; Kelly, CM (2013) 'Chemotherapy' In: Palmieri, C; Simcock, R; Bird, E (eds). ABC of Cancer Care. Oxford: John Wiley and Sons. [Details]
Kelly, CM; Buzdar, AU (2012) 'Adjuvant endocrine therapy for breast cancer in postmenopausal women' In: Esteva, F; Babiera, G; Skoracki, R (eds). Advanced Therapy of the Breast. London: BC Decker Inc. [Details]
Kwon, DS; Kelly, CM; Feig, BW; Babiera, GV (2012) 'Breast Cancer' In: Feig, BW; Ching, DC (eds). M.D Anderson Cancer Center, Surgical Oncology handbook. New York: Lippincott, Williams and Wilkins. [Details]
Kelly, CM; Buzdar, AU (2012) 'Endocrine therapy for metastatic disease in postmenopausal women with breast cancer' In: Esteva, F; Babiera, G; Skoracki, R (eds). Advanced Therapy of the Breast. London: BC Decker Inc. [Details]
Pusztai, L; Kelly, CM (2011) 'Systemic adjuvant therapy for Stage I breast cancer' In: Kahan, S; Tot, T (eds). Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages. Dordrecht: Springer. [Details]
Pusztai, L; Kelly, CM (2009) 'Chemotherapy as Targeted Therapy for Breast Cancer' In: Sledge; Baselga (eds). Targeted Therapies in Breast Cancer. New York: BC Decker Inc. [Details]
Kelly, CM; Penny, S; Ryan, D; Gallagher, WJ (2008) 'Systematic Validation of Breast Cancer Biomarkers Using Tissue Microarrays: From Construction to Image Analysis' In: Hyatt, MA (eds). Methods of Cancer diagnosis, Therapy, and Prognosis. Netherlands: Springer. [Details]
Kelly, CM; Siow Lee, M; Steele, J (2005) 'Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer' In: Myers, M (eds). The Effective Management of Lung Cancer: UK Key Advances in Clinical Practice Series. London: Aesculapius Press. [Details]

Peer Reviewed Journals

Kelly, CM; Smith, M; Flynn, S; Reyes, A; Higgins, M; Mc Caffrey, J; Kelly, CM (2016) 'Accrual to cancer clinical trials in Ireland. Accepted for publication'. Irish Medical Journal, . [Details]
Iwamoto T, Kelly C;Mizoo T;Nogami T;Motoki T;Shien T;Taira N;Hayashi N;Niikura N;Fujiwara T;Doihara H;Matsuoka J (2016) 'Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer'. Clinical Breast Cancer, 16 (2):95-1000. [DOI] [Details]
Jones M, O'Gorman P;Kelly C;Mahon N;Fitzgibbon MC (2016) 'High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury'. Annals of Clinical Biochemistry, . [DOI] [Details]
Kelly, D; Watson, G; Kelly, CM (2016) 'Clinical overview of thyroid cancer and recent advances'. Journal of Oncology Practice, . [Details]
Smyth L, Watson G;Walsh EM;Kelly CM;Keane M;Kennedy MJ;Grogan L;Hennessy BT;O'Reilly S;Coate LE;O'Connor M;Quinn C;Verleger K;Schoeman O;O'Reilly S;Walshe JM (2015) 'Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland'. Breast Cancer Research and Treatment, 153 (3):573-582. [DOI] [Details]
Sugiu K, Iwamoto T;Kelly CM;Watanabe N;Motoki T;Ito M;Ohtani S;Higaki K;Imada T;Yuasa T;Omori M;Sonobe H;Fujiwara T;Matsuoka J (2015) 'Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial'. Acta Medica Okayama, 69 (5):291-299. [Details]
Cahir C, Dombrowski SU;Kelly CM;Kennedy MJ;Bennett K;Sharp L (2015) 'Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour'. Supportive Care in Cancer, 23 (11):3115-3130. [DOI] [Details]
Farrell J, Kelly C, Rauch J, Kida K, García-Muñoz A, Monsefi N, Turriziani B, Doherty C, Mehta JP, Matallanas D, Simpson JC, Kolch W, von Kriegsheim A (2014) 'HGF induces epithelial-to-mesenchymal transition by modulating the mammalian hippo/MST2 and ISG15 pathways'. Journal of Proteome Research, 13 (6):2874-2886. [DOI] [Details]
Bianchini G, Pusztai L;Karn T;Iwamoto T;Rody A;Kelly C;M¿¿ller V;Schmidt S;Qi Y;Holtrich U;Becker S;Santarpia L;Fasolo A;Del Conte G;Zambetti M;Sotiriou C;Haibe-Kains B;Symmans WF;Gianni L (2014) 'Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers'. Breast cancer research : BCR, 15 (5). [DOI] [Details]
Partridge AH, Pagani O;Abulkhair O;Aebi S;Amant F;Azim HA;Costa A;Delaloge S;Freilich G;Gentilini OD;Harbeck N;Kelly CM;Loibl S;Meirow D;Peccatori F;Kaufmann B;Cardoso F (2014) 'First international consensus guidelines for breast cancer in young women (BCY1)'. Breast, 23 (3):209-220. [DOI] [Details]
Lyons TG, O'Kane GM;Kelly CM (2014) 'Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma'. Expert Opinion on Drug Safety, 13 (8):1125-1132. [DOI] [Details]
O'Kane GM, Lyons TG;Colleran GC;Ahmad MW;Alken S;Kavanagh EC;Fitzpatrick D;Murray B;Kelly CM (2014) 'Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma'. Oncology Research and Treatment, 37 (12):757-760. [DOI] [Details]
O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM (2013) 'Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer'. BMC Cancer, 13 (175). [DOI] [Details]
Alken S, Kelly CM (2013) 'Benefit risk assessment and update on the use of docetaxel in the management of breast cancer'. Cancer Management and Research, 5 :357-365. [DOI] [Details]
Kelly CM, Buzdar AU (2013) 'Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer'. Drugs, 73 (6):505-515. [DOI] [Details]
Jordan EJ, Kelly CM (2012) 'Vemurafenib for the treatment of melanoma'. Expert Opinion on Pharmacotherapy, 13 (17):2533-2543. [DOI] [Details]
O'Sullivan Coyne G, Walsh J;Kelly CM (2012) 'Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer'. Expert Opinion on Drug Safety, 11 (4):643-650. [DOI] [Details]
Kelly CM, Bernard PS;Krishnamurthy S;Wang B;Ebbert MT;Bastien RR;Boucher KM;Young E;Iwamoto T;Pusztai L (2012) 'Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX¿¿) and the PAM50 breast cancer intrinsic Classifier¿¿¿ in early-stage estrogen receptor-positive breast cancer'. Oncologist, 17 (4):492-498. [DOI] [Details]
Kelly CM, Green MC;Broglio K;Thomas ES;Brewster AM;Valero V;Ibrahim NK;Gonzalez-Angulo AM;Booser DJ;Walters RS;Hunt KK;Hortobagyi GN;Buzdar AU (2012) 'Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer'. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 (9):930-935. [DOI] [Details]
Kelly CM, Buzdar AU (2012) 'Aromatase inhibitors in premenopausal breast cancer'. The Lancet. Oncology, 13 (4):320-321. [DOI] [Details]
Kelly CM, Pritchard KI;Trudeau M;Andreopoulou E;Hess K;Pusztai L (2011) 'Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?'. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 22 (11):2387-2393. [DOI] [Details]
Pusztai L, Viale G;Kelly CM;Hudis CA (2010) 'Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis'. Oncologist, 15 (11):1164-1168. [DOI] [Details]
Kelly CM, Buzdar AU (2010) 'Anastrozole'. Expert Opinion on Drug Safety, 9 (6):995-1003. [DOI] [Details]
Kelly CM, Krishnamurthy S;Bianchini G;Litton JK;Gonzalez-Angulo AM;Hortobagyi GN;Pusztai L (2010) 'Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers'. Cancer, 116 (22):5161-5167. [DOI] [Details]
Kelly CM, Hortobagyi GN (2010) 'Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?'. Surgical Oncology Clinics of North America, 19 (3):649-668. [DOI] [Details]
Kelly CM, Warner E;Tsoi DT;Verma S;Pritchard KI (2010) 'Review of the clinical studies using the 21-gene assay'. Oncologist, 15 (5):447-456. [DOI] [Details]
Tsoi DT, Inoue M;Kelly CM;Verma S;Pritchard KI (2010) 'Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer'. Oncologist, 15 (5):457-465. [DOI] [Details]
Kelly CM, Juurlink DN;Gomes T;Duong-Hua M;Pritchard KI;Austin PC;Paszat LF (2010) 'Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study'. BMJ (Clinical research ed.), 340 . [Details]
Tsoi DT, Rowsell C;McGregor C;Kelly CM;Verma S;Pritchard KI (2010) 'Disseminated tumor embolism from breast cancer leading to multiorgan failure'. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (12):1-3. [DOI] [Details]
Kelly CM, Buzdar AU (2010) 'Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial'. Expert Opinion on Pharmacotherapy, 11 (3):489-492. [DOI] [Details]
Martin P, Kelly CM;Carney D (2006) 'Epidermal growth factor receptor-targeted agents for lung cancer'. Cancer Control, 13 (2):129-140. [Details]

Conference Publications

Cardoso, F; Bartlett, J; Slaets, L; van Deurzen, C; van Leewen-Stok, E; Porter, P; Linderholm, B; Hedenfalk, I; Schroder, C; Martens, J; Bayani, J; van Asperen, C; Murray, M; Hudis, C; Middleton, L; Vermeij, J; Peeters, S; Fraser, J; Nowaczyk, M; Rubio, I; Aebi, S; Kelly, C; Ruddy, K; Winer, E; Nilsson, C; Dal Lago, L; Korde, L; Benstead, K; Van Den Weyngaert, D; Bogler, O; Goulioti, T; Dif, N; Messina, C; Tryfonidis, K; Bogaerts, J; Giordano, S (2016) Pathologic prognostic factors of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABG International Male Breast Cancer Program 10th European Breast Cancer Conference [Details]
Krop, I; Abramson, V; Colleoni, M; Holmes, F; Estevez, L; Hart, L; Awada, A; Zamagni, C; Morris, P; Schwartzberg, L; Chan, S; Wheatley, D; Guculp, A; Biganzoli, L; Steinberg, J; Gianni, L; Trudeau, M; Kelly, C; Uppal, H; Tudor, C; Peterson, A; Yardley, D (2016) Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor¿positive breast cancer San Antonio Breast Cancer Symposium [Details]
Cardoso, F; Bartlett, J; Slaets, L; van Deurzen, C; van Leewen-Stok, E; Porter, P; Linderholm, B; Hedenfalk, I; Schroder, C; Martens, J; Bayani, J; van Asperen, C; Murray, M; Hudis, C; Middleton, L; Vermeij, J; Peeters, S; Fraser, J; Nowaczyk, M; Rubio, I; Aebi, S; Kelly, C; Ruddy, K; Winer, E; Nilsson, C; Dal Lago, L; Korde, L; Benstead, K; Van Den Weyngaert, D; Bogler, O; Goulioti, T; Dif, N; Messina, C; Tryfonidis, K; Bogaerts, J; Giordano, S (2015) Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program San Antonio Breast Cancer Symposium [Details]
Traina, TA; Miller, K; Yardley, DA; O'Shaughnessy, J; Cortes, J; Awada, A; Kelly, C; Trudeau, M; Schmid, P; Gianni, L; Garcia-Extevez, L; Nanda, R; Ademuyiwa, F; Chan, S; Steinberg, JL; Blaney, M; Tudor, IC; Uppal, H; Peterson, A; Hudis, CA (2015) Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) ASCO Annual Meeting 2015 [Details]


Jordan, EJ,Kelly, CM (2012) Vemurafenib for the treatment of melanoma. Editorial [DOI] [Details]


Dolan, RT,Penny, S,Kelly, CM,Brennan, DJ,Rexhepaj, E,Jirstrom, K,Ponten, F,Uhlen, M,Gallagher, WM,Kell, MR (2011) Development of immunohistochemical surrogates for prediction of breast cancer patient outcome via high-throughput antibody generation and validation using tissue microarray technology. Abstract [Details]
Kelly, CM,Penny, S,Brennan, D,O'Brien, S,Fagan, A,Culhane, AC,Jirstrom, K,Ponten, F,Uhlen, M,Gallagher, WM (2008) Systematic validation of novel breast cancer progression-associated biomarkers via high-throughput antibody generation and application of tissue microarray technology: An initial report. Abstract [Details]


Research Interests



Phase III study evaluating palbociclib (PD‐0332991), a Cyclin‐Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone‐receptor‐positive, HER2‐normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy


A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive / HER2 negative Advanced breast cancer and documented Endocrine resistance (PASIPHAE)


Open-label, international, randomized phase III neoadjuvant study of MPDL3280A, carboplatin and nab-paclitaxel compared to the control arm of carboplatin and abraxane


A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician¿s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) ¿ (KEYNOTE-119)


A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE)


SWOG-S1007. A phase III randomised clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone responsive and HER2 negative breast cancer according to recurrence score.


MDV-3100-12.  A placebo controlled randomized study comparing exemestane +/- enzalutamide in patients with ER/PgR+ (AR any) disease


A phase II single arm open-label multicenter study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple negative breast cancer.





EORTC 10085-Male Breast Cancer: Clinical and biological characterization of male breast cancer: an international EORTC, BIG, TBCRC and NABCG Intergroup study


ICORG 12-30. Breast Cancer Bank of Tissue from Trial Assigning Individualised Options for Treatment (TAILORx Tissue Bank)


CRQ Survey Study: Clinical Research Questionnaire of Oncology Patients ¿ A Nationwide Survey ICORG 15-43

Evaluate oncology patients¿ understanding of the term ¿clinical

trials¿ and their attitudes towards personal participation in cancer clinical research


Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour.  Development of interventions to improve adherence to endocrine therapies.

UCD Medicine Research Individual Investigators 


Recent Postgraduates

Dr Ciara Kelly Medical Oncology Specialist Registrar.

MD Thesis Defence: September 2016

Understanding and attitudes towards Cancer Clinical Trials among patients with cancer.  A cross sectional cohort study


Dr Lisa Prior Medical Oncology Specialist Registrar

MD Thesis:  Assessment of competing risks in women with early stage breast cancer receiving chemotherapy.


Dr Emily Harrold Medical Oncology Specialist Registrar: Cervical Adenocarcinoma and Ovarian Cancer Genomic Analysis

Current Postgraduate Students

Ciara Kelly, Medicine (MD)   -   Thesis Supervisor


Internal Collaborators

Prof. William Gallagher, School of Biomolecular and Biomedical Science, Conway Institute, UCD

Prof. Kathleen Bennett, Royal College of Surgeons in Ireland

Dr Caitriona Cahir, Royal College of Surgeons in Ireland

Dr Darran O Connor, Royal College of Surgeons in Ireland

Dr Sudipto Das, Royal College of Surgeons in Ireland

Dr Niall Mulligan, Consultant Pathologist, Mater Misericordiae University Hospital

External Collaborators

Lajos Pusztai, MD, DPhil, Chief of Breast Medical Oncology; Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program


Prof. Constance Albarracin ( Department of Surgical Pathology, University of Texas, M.D. Anderson Cancer Center.


Prof. Kathleen Pritchard, Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, Canada. Email:


Prof. Larry Paszat, Institute of Clinical Evaluative Sciences, Sunnybrook Health Sciences Center, Toronto, Canada. University of Toronto School of Health Policy, Management and Evaluation. Email: